Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg

Contraception

Volumn 74, Issue 3, 2006, Pages 234-238

  Arias, Raquel D ^a   Jain, John K ^a   Brucker, Cosima ^b   Ross, Doug ^c   Ray, Amrit ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b KLINIKUM NÜRNBERG   (Germany)

^c Pfizer Global Pharmaceuticals   (United States)

Author keywords

Amenorrhea; Contraception; Depot medroxyprogesterone acetate subcutaneous (DMPA SC)

Indexed keywords

MEDROXYPROGESTERONE ACETATE;

ADULT; AGE DISTRIBUTION; AMENORRHEA; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; MENSTRUATION; MENSTRUATION DISORDER; SPOTTING; UTERINE BLEEDING PATTERN;

ADULT; AMENORRHEA; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MEDROXYPROGESTERONE 17-ACETATE; MEDROXYPROGESTERONE ACETATE; MENSTRUAL CYCLE; UTERINE HEMORRHAGE;

EID: 33746782160     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.03.008     Document Type: Article

References (18)

1. Jain J., Jakimiuk A.J., Bode F.R., Ross D., and Kaunitz A.M. Contraceptive efficacy and safety of DMPA-SC. Contraception 70 (2004) 269-275
2. Jain J., Dutton C., Nicosia A.F., Wajszczuk C., Bode F.R., and Mishell Jr. D.R. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera®. Contraception 70 (2004) 11-18
3. Toh Y.C., Jain J., Rahimy M.H., Bode F.R., and Ross D. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 ml) contraceptive formulation in Asian women. Clin Ther 26 (2004) 1845-1854
4. Belsey E.M., and Pinol A.P. Menstrual bleeding patterns in untreated women. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 55 (1997) 57-65
5. Belsey E.M., Machin D., and D'arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 34 (1986) 253-260
6. Schwallie P.C., and Assenzo J.R. Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 24 (1973) 331-339
7. Nelson A.L. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. J Reprod Med 41 (1996) 391-400
8. Canto De Cetina T.E., Canto P., and Luna M.O. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 63 (2001) 143-146
9. Lei Z.-W., Wu S.C., Garceau R.J., et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 53 (1996) 357-361
10. Hubacher D., Goco N., Gonzalez B., and Taylor D. Factors affecting continuation rates of DMPA. Contraception 60 (2000) 345-351
11. Kaunitz A.M. Menstruation: choosing whether... and when. Contraception 62 (2000) 277-284
12. Thomas S.L., and Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women?. Lancet 355 (2000) 922-924
13. Eaton S.B., Pike M.C., Short R.V., et al. Women's reproductive cancers in evolutionary context. Q Rev Biol 69 (1994) 353-367
14. Arias R.D. Hormonal contraceptives and menstrual changes: strategies for effective counseling. Female Patient 28 (2003) 12-23
15. Kaunitz A.M. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil 43 (1998) 73-83
16. Cullins V.E. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med 41 Suppl (1996) 428-433
17. Glasier A.F., Smith K.B., van der Spuy Z.M., et al. Amenorrhea associated with contraception-an international study on acceptability. Contraception 67 (2003) 1-8
18. den Tonkelaar I., and Oddens B.J. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 59 (1999) 357-362